TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
June 27 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine and wellness company, today announced that
its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human
Performance product, has been selected to be a part of the Air
Force Research Laboratories (AFRL) Real-Time Assessing and
Augmenting Cognitive Performance in Extreme Environments (A2PEX)
Grant Program. A2PEX is a five-year project led by the Florida
Institute for Human and Machine Cognition (IHMC) that includes
internationally-recognized leaders in wearable technologies from
industry and academia.
The goal of A2PEX is to build a wearable system to sense, assess
and augment cognitive performance in operational environments.
Sensors developed by A2PEX partners will develop
electrophysiological and biomarker sensors to assess Airmen
stress/fatigue in extreme environments. electroCore’s proprietary
TAC-STIM nVNS has been commissioned by IHMC for integration into
the A2PEX system to mitigate fatigue and augment performance.
TAC-STIM is a form of nVNS for human performance and has been
developed in collaboration with the United States Department of
Defense Biotech Optimized for Operational Solutions and Tactics, or
"BOOST" program and AFRL.
The Air Force has identified the need to develop novel materials
and wearable devices to assess and augment Airman cognitive
performance in aerospace environments such as multi-day
transoceanic operational and logistic flights as well as long
duration remotely piloted aircraft missions. Fatigue resulting from
these extreme stressors can evolve into chronic health problems,
and cause decrements in judgement and vigilance resulting in severe
aviation mishaps. A 2020 National Commission on Military Aviation
Safety report concluded that the more than 6,000 military aviation
accidents that killed 224 pilots or aircrew were largely a result
of chronic fatigue1.
Dr. Regina Shia, AFRL’s Project manager for A2PEX
commented, “The development of an integrated system that can sense,
assess, and augment the performance of our Airmen and Airwomen is
integral to the mission of AFRL and a high priority of the United
States Air Force.” Dr. Timothy Broderick, Chief Science
Officer, Senior Research Scientist at IHMC and Co-Primary
Investigator of A2PEX added, “We are pleased to have assembled a
group of leading human performance partners to deliver a product
that can meet the needs of the Air Force. TAC-STIM was selected for
this project based on its demonstrated ability to mitigate fatigue
and improve performance in several relevant environments.”
“We are honored to have been selected to be a part of the A2PEX
program,” said Dan Goldberger, Chief Executive Officer at
electroCore. “We look forward to working with our A2PEX partners to
developing a system that can further support our servicemen and
women in their critical missions.”
About The Air Force Research LaboratoryThe Air
Force Research Laboratory is the primary scientific research and
development center for the Department of the Air Force. AFRL plays
an integral role in leading the discovery, development, and
integration of affordable warfighting technologies for our air,
space, and cyberspace force. With a workforce of more than 11,500
across nine technology areas and 40 other operations across the
globe, AFRL provides a diverse portfolio of science and technology
ranging from fundamental to advanced research and technology
development. For more information, visit:
www.afresearchlab.com.
About Florida Institute for Human and Machine
Cognition IHMC is a not-for-profit research institute of
the Florida University System where researchers pioneer science and
technology aimed at leveraging and extending human capabilities.
IHMC researchers and staff collaborate extensively with the
government, industry and academia to help develop breakthrough
technologies. IHMC research partners have included: DARPA, the
National Science Foundation, NASA, Army, Navy, Air Force, National
Institutes of Health, IBM, Microsoft, Honda, Boeing, Lockheed, and
many others.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements regarding the results from work being conducted by AFRL
under the A2PEX Grant Program, anticipated results and timing of
wearable system development being conducted with TAC-STIM nVNS,
electroCore's business prospects, its sales and marketing and
product development plans, future cash flow projections,
anticipated costs, its product portfolio or potential markets for
its technologies, the availability and impact of payor coverage,
the potential of nVNS generally and TAC-STIM nVNS in particular to
mitigate fatigue and augment performance, and other statements that
are not historical in nature, particularly those using terminology
such as "anticipates," "expects," "believes," "intends," other
words of similar meaning, derivations of such words and the use of
future dates. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to obtain additional
financing necessary to continue electroCore's business, sales and
marketing and product development plans, the uncertainties inherent
in the development of new products or technologies, the ability to
successfully commercialize TAC-STIM™, competition in the industry
in which electroCore operates and general market conditions. The
results of earlier preclinical studies and clinical trials may not
be predictive of results of future preclinical studies, clinical
trials, or commercial success. All forward-looking statements are
made as of the date of this press release, and electroCore
undertakes no obligation to update forward-looking statements or to
update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law. Investors should refer to all information set forth in this
document and should also refer to the disclosure of risk factors
set forth in the reports and other documents electroCore files with
the SEC, available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
1
https://thehill.com/policy/defense/528689-report-on-military-aviation-crashes-faults-lack-of-training-chronic-fatigue/
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024